Fig. 1: Bar graph of efficacy endpoints of immune checkpoint inhibitors in compared timing groups from 18 studies involving a total of 3250 patients with different cancer types.
From: Why does circadian timing of administration matter for immune checkpoint inhibitors’ efficacy?
a Median progression-free survival data. b Median overall survival data. Violet bars correspond to late time-of-day ICI dosing. Blue bars correspond to early time-of-day of ICI administration. The main characteristics of these studies are summarized in Table S1. Note: Qian et al. study results not shown despite statistically significant differences in overall survival in favor of the early time-of-day group, because median values were not reached Reported p values from timing groups comparisons of PFS or survival curves: *P > 0.20; ** 0.05 < p ≤ 0.20; *** 0.01 < p ≤ 0.05; ****0.001 < p ≤ 0.01.
